Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...

Analysts expressed concerns about R&D spending, vaccine sales uncertainties ... s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in ...

In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.

P.E.I.'s chief public health officer is working towards expanding eligibility for RSV vaccines as the province experiences high levels of respiratory illnesses this season. Dr. Heather Morrison ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines ... and Daiichii Sankyo’s antibody-drug ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...

Over a third of women giving birth got the new RSV vaccine in September, protecting newborns from severe illness. The new maternal Respiratory Syncytial Virus (RSV) vaccine rolled out in September saw ...